- Open Access
Correction to: SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease
Cardiovascular Diabetology volume 17, Article number: 38 (2018)
- The original article was published in Cardiovascular Diabetology 2017 16:65
Correction to: Cardiovasc Diabetol (2017) 16:65 https://doi.org/10.1186/s12933-017-0547-1
Following publication of the original article  the authors reported that the first affiliation (“Medical Center of the Graduate School, Nanchang University, China”) had been added in error, and that the correct author information is as given in this erratum.
Zou H, Zhou B, Gaosi X. SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease. Cardiovasc Diabetol. 2017;16:65. https://doi.org/10.1186/s12933-017-0547-1.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
The original article can be found online at https://doi.org/10.1186/s12933-017-0547-1.
About this article
Cite this article
Zou, H., Zhou, B. & Xu, G. Correction to: SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease. Cardiovasc Diabetol 17, 38 (2018). https://doi.org/10.1186/s12933-018-0676-1